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Immunoglobulin G4- related disease (IgG4-RD) is a rare systemic fibro-inflammatory disorder (ORPHA284264).
Although patients have been described more than 100 years ago, the systemic nature of this disease has been
recognized in the 21st century only. Type 1 autoimmune pancreatitis is the most frequent manifestation of IgG4-RD.
However, IgG4-RD can affect any organ such as salivary glands, orbits, retroperitoneum and many others. Recent
research enabled a clear clinical and histopathological description of IgG4-RD. Typically, lymphoplasmacellular
inflammation, storiform fibrosis and obliterative phlebitis are found in IgG4-RD biopsies and the tissue invading
plasma cells largely produce IgG4. Elevated serum IgG4 levels are found in many but not all patients. Consequently,
diagnostic criteria for IgG4-RD have been proposed recently. Treatment is largely based on clinical experience and
retrospective case series. Glucocorticoids are the mainstay of therapy, although adjunctive immunosuppressive
agents are used in relapsing patients. This review summarizes current knowledge on clinical manifestations,
pathophysiology and treatment of IgG4-RD.
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Immunoglobulin G4- related disease (IgG4-RD) is a sys-
temic fibro-inflammatory disorder of unknown origin.
While single organ manifestations have been described
already more than 100 years ago, a clear description and
nomenclature of this disease have been achieved in the
past 10 years. As IgG4-RD may affect virtually every organ,
this disease is of interest not only for internal medicine
physicians but also for other specialties such as ear nose &
throat, dermatology, ophthalmology, and neurology.Case vignette
In January 2012, a 61 year- old female presented to a
rheumatology unit with a long- standing history of recur-
rent inflammatory lesions of unknown origin since 1989,
which had been previously diagnosed as pseudolymphoma
and Sjögren’s syndrome (SS). The leading symptom
was bilateral orbital masses, which eventually led to* Correspondence: herwigpi@yahoo.com
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unless otherwise stated.enucleation of the left eye. Further, suspicious enlarged
lymph nodes in the head and neck region as well as recur-
rently enlarged salivary glands were evident. Moreover,
paravertebral masses as well as thickening of ocular
muscles and nerves were present.
The patient underwent a series of organ biopsies over
the years including resections of the orbital pseudo-
tumor and left submandibular salivary gland, as well as
biopsies of ocular muscles. All biopsies showed dense
lymphoplasmacellular infiltrates of the respective organs.
Due to the lack of evidence for monoclonal disease
based on these biopsies and inconspicuous bone marrow
investigations, the results were interpreted as “pseudo-
lymphoma”. Nonetheless, the patient received treatments
such as chlorambucil and radio-chemotherapy. All pred-
nisone- containing treatment schemes were successful in
decreasing mass sizes and organ swellings for a short
period. However, the patient’s disease course was chronic
relapsing during the first years. In the last 8 years before
referral, however, the disease changed to a more chronic,
stable course without major complications.
When we saw the patient first in 2012, her medication
included azathioprine 100 mg and prednisone 5 mg peral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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changed during the last years. Otherwise, she was in
good condition. Upon physical examination, mild swelling
of the right submandibular gland was evident. On im-
aging, we found massive thickening of the ocular nerves
(Figure 1A). Laboratory examination revealed negative anti-
nuclear antibodies (ANA), extractable nuclear antigens
(ENA), anti-neutrophil cytoplasmic antibodies (ANCA),
rheumatoid factor, normal complement C3 and C4, and
no cryoglobulins. Erythrocyte sedimentation rate (ESR),
C- reactive protein (CRP) and blood chemistry were within
normal range. However, total IgG levels were slightly
elevated with IgG4 being strongly elevated (519 mg/dl,
normal 5 – 125 mg/dl).
We retrieved biopsies of the ocular muscles, parotid
gland and the left submandibular gland and asked the
pathology department for re-evaluation of the specimens
and staining for plasma cells, IgG and IgG4. All speci-
mens revealed dense infiltration of IgG4- producing
plasma cells with a highly increased tissue IgG4/IgG
ratio of >40% (Figure 1B). Further, tissue eosinophilia,
storiform fibrosis and obliterative phlebitis were present,
thus confirming the diagnosis of IgG4- RD.
History
The first descriptions of IgG4-RD organ manifestations
were published in the late 19th century. In 1892, Johann
von Mikulicz - a scholar of Theodor Billroth - first
described a patient with an inflammatory disease of
the salivary glands (Mikulicz’ syndrome) [1]. Subse-
quently, Küttner described in 1896 a patient suffering
from a tumor-like lesion of the submandibular glands
(Küttner’s tumor) [2]. In the same year, Riedel reported on
“eisenharte Struma”, a condition characterized by a stone-
hard, fibrous transformation of the thyroid gland and
adjacent tissue [3]. However, the true nature of these
disease manifestations remained unclear for another
century.
Many organ manifestations of IgG4-RD including among
others retroperitoneal fibrosis, sclerosing cholangitis, and
sclerosing pancreatitis have since been described. Already
decades ago, the systemic nature of the disease was recog-
nized as evidenced by patients presenting with more than
one organ involvement. For instance, Bartholomew et al.
reported in 1963 on two patients with a combination of
Riedel’s thyroiditis, retroperitoneal fibrosis and sclerosing
cholangitis [4].
Significant progress was made in 1995, when a patient
with a steroid- responsive form of pancreatitis was re-
ported of presumed autoimmune origin (autoimmune pan-
creatitis, AIP) [5]. Later, in 2001 Hamano et al. reported
elevated IgG4 levels in AIP patients and, finally, in 2002
infiltration of IgG4-bearing plasma cells in tissue samples
from patients with “sclerosing pancreatitis” (as well as inconcomitant retroperitoneal fibrosis) were documented by
the same group [6,7].
These findings have been replicated in different co-
horts of patients with the above- described syndromes
[8,9]. Thus, a distinct disease entity comprising patients
presenting with inflammatory and/or fibrosing single or
multiple organ lesions in conjunction with elevated
serum IgG4 levels and tissue IgG4 production became
clear. While different names for this syndrome were
used in the past 10 years, the term “IgG4- related disease”
has recently evolved as most appropriate [10]. Con-
sequently, the organ manifestations of IgG4-RD were
renamed and eponyms were abandoned (Table 1).
Diagnosis and pathology
IgG4-RD can affect any organ or tissue. Thus, the clin-
ical picture is highly heterogeneous. While some patients
may present with a single site involved, others may have
a few or many organs affected by IgG4-RD. These may
arise synchronously or metachronously. The disease may
manifest as a tumefactive lesion or a rather diffuse infil-
trative process, further contributing to a diverse clinical
picture. In addition, some organs show a distinct in-
volvement, as for instance lymphadenopathy, periaortitis,
or a secondary form of membranous glomerulonephritis
(GN) [11-13].
Laboratory findings in IgG4-RD are often inconspicu-
ous. Inflammatory markers such as ESR and CRP may
be highly elevated, but can be normal despite active dis-
ease in a substantial proportion of patients. Anti-nuclear
antibodies, anti- SS-A as well as anti- SS-B antibodies
are negative in the majority of patients, while low com-
plement levels (C3 and C4) are not uncommon [14,15].
Polyclonal hypergammaglobulinemia is often found in
IgG4-RD. Increased serum IgE levels and allergic dis-
eases are present in about one third of patients [16]. IgG
subclass analyses reveal highly elevated serum IgG4
levels in many but not all patients. It should be under-
lined that IgG4 levels can be substantially misleading
when they are used as a sole criterion for diagnosis (or
exclusion) of IgG4-RD. On the one hand, a number of
other diseases, such as cancer, infections and auto-
immune diseases, including vasculitis, are associated
with increased IgG4 levels [17]. On the other hand, a
number of IgG4-RD patients may have normal IgG4
levels. Thus, the sensitivity of IgG4 in IgG4-RD was
found to be 90% and the specificity 60% in one study
[18]. In another study the positive predictive value of an
elevated serum IgG4 for IgG4-RD was found to be as
poor as 10% [19].
In some patients with active IgG4-RD IgG4 levels were
found to be inappropriately low due to the prozone
effect, a situation where too many antibodies prevent
agglutination of antigenic particles in the test system. If
AB
Figure 1 A: IgG4- related disease with involvement of the orbits, ocular nerves and salivary glands. Contrast- enhanced T1 weighed
magnetic resonance coronal imaging of the head showing massive thickening of the infraorbital nerve (red arrow). B: Histopathological examination
of orbital muscle (upper panel) and parotid gland biopsies (lower panel) reveals dense lymphoplasmacellular infiltration and fibrosis (left pictures, HE
staining) with dense infiltration of IgG4- producing plasma cells (right pictures, anti-IgG4, rabbit monoclonal, 1:1000 a.r., Abcam, Cambridge, UK).
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dilution may lead to correction of the prozone effect and
reveal – appropriately – much higher IgG4 levels in par-
ticular patients [20].While the location of disease manifestation may vary,
the histological pattern is – with some exceptions –
more or less uniform and shares particular features: (i)
storiform fibrosis (resembling the spokes of a cartwheel),
Table 1 Nomenclature for manifestations in different organ systems [adapted from Stone JH et al. A&R [10]]
Pancreas IgG4-related pancreatitis (Type 1 autoimmune pancreatitis)
Bile ducts, gallbladder and liver IgG4-related sclerosing cholangitis
IgG4-related cholecystitis
IgG4-related hepatopathy
Thyroid gland IgG4-related thyroid disease
Salivary and lacrimal glands IgG4-related sialadenitis
IgG4-related parotitis
IgG4-related submandibular gland disease
IgG4-related dacryoadenitis
Orbits IgG4-related ophthalmic disease
IgG4-related orbital inflammatory pseudotumor
IgG4-related pan-orbital inflammation
IgG4-related orbital myositis
Retroperitoneal fibrosis, arteries IgG4-related retroperitoneal fibrosis
IgG4-related aortitis/periaortitis
IgG4-related periarteritis
Intrapulmonary, mediastinal and pleural involvement IgG4-related lung disease
IgG4-related mediastinitis
IgG4-related pleuritis
Lymph nodes IgG4-related lymphadenopathy
Kidney IgG4-related kidney disease
tubulointerstitial nephritis secondary to IgG4-related disease
membranous glomerulonephritis secondary to IgG4-related disease
IgG4-related renal pyelitis










*Novel clinical IgG4-RD manifestations have been proposed since the original publication and were therefore included in this overview.
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number of IgG4+ plasma cells (at least > 10/high power
field (HPF) – depending on the particular organ) and/or
an increased IgG4/IgG ratio (usually >40%) and (iii) an
obliterative phlebitis. Tissue eosinophilia is also very
characteristic. The presence of neutrophils, granulomas,
neutrophilic microabscesses, and necrotizing vasculitis
strongly argues against IgG4-RD [21]. In some organs,
IgG4-RD can manifest with distinct histopathological
features, e.g. in kidney and lymph nodes (see section on
clinical manifestations). Recently, a Japanese study groupproposed diagnostic criteria for IgG4-RD in general
(Figure 2) [22]. In addition, there have been proposals
for diagnostic criteria of organ- specific IgG4-RD manifes-
tations such as in kidney or pancreatic disease [23,24].
Epidemiology
There are few studies reporting on the epidemiology of
IgG4-RD, mainly derived from Asian studies. A cross-
sectional study in 2009 estimated that approximately
8000 individuals in Japan were suffering from IgG4-RD,
thus accounting for a prevalence of approx. 60 affected
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Figure 2 Comprehensive diagnostic criteria for IgG4- related disease (modified after Umehara et al. [22]). *Histopathology suggestive of
IgG4-RD, e.g. lymphoplasmacytic infiltration and fibrosis.
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males were affected and mean age was 58 years well in
line with previous reports. There are no data on the
prevalence of IgG4-RD in Europe or elsewhere, but
IgG4-RD is thought to be rarer in these areas. IgG4-RD
usually affects middle-aged individuals and at least for
some organ manifestations such as type 1 AIP a male
predominance is evident.
Pathophysiology
Little is known about the initiation process of IgG4-RD
or how and why these specific organ infiltrations occur.
There is some evidence from Asian populations, that
certain HLA alleles – particularly DRB1*0405 and
DQB*0401 – increase the susceptibility to type 1 AIP [26].
Further, few single- nucleotide polymorphisms (SNP) in
genes related to immune system such as CTLA-4 and
Fc- receptor-like 3 have been linked to IgG4-RD
[27,28]. In AIP, autoantibodies against the plasminogen-
binding protein of H. pylori were found in the majority of
patients in one study [29]. Plasminogen- binding protein
of H. pylori shares homology to a protein expressed in
pancreatic acinar cells. The authors hypothesized, that
through molecular mimicry this immune response could
lead to IgG4-RD.
It is suspected but unclear, whether IgG4-RD truly
belongs to the group of autoimmune disorders. There is
evidence of autoantibodies such as ANA, rheumatoid
factor, and others in some patients [30]. However, these
autoantibodies are far beyond from being specific forIgG4-RD. The same is true for organ- specific autoanti-
bodies to proteins expressed for instance in the pancreas
or bile ducts [31].
In contrast to many autoimmune disorders, IgG4-RD
seems to have a skewed T- cell response towards a TH2
phenotype. Increased tissue levels of TH2-cytokines such
as Interleukin-4 (IL-4), −5 (IL-5) and −13 (IL-13) were
found in IgG4-RD [32]. Further, 40% of IgG4-RD pa-
tients have increased serum IgE levels and allergic dis-
eases are common [16]. Moreover, tissue eosinophilia is
typical for IgG4-RD [33]. Some studies also suggested an
increased activation of regulatory T cells (Treg), which
might be due to the over-expression of transforming
growth factor β (TGF-β), an important regulator of Treg
development [34,35]. Previously it could be demon-
strated that the expression of IgG4 class switch-related
molecules is different in labial salivary glands and peri-
pheral blood mononuclear cells. In glands of IgG4-RD
patients upregulated Treg cytokines such as IL-10 and
TGF-β appear to play pathogenic roles in IgG4-specific
class-switch recombination and fibrosis. Activation-
induced cytidine deaminase (AID), as a marker of non-
specific immunoglobulin class-switch recombination, was
also found to be increased in labial salivary glands of
IgG4-RD patients and could contribute to upregulation
of IgG4-specific class-switch recombination. IgG4 class-
switch recombination seemed to be mainly upregulated in
affected organs [36].
Well-fitting to a TH2 immune response, IgG4-RD is
characterized by both systemic and localized IgG4
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bodies are acting as pathogenic antibodies or are just
a bystander phenomenon. In healthy individuals, IgG4
is the least abundant IgG subclass molecule accounting
for less than 5% of total IgG [37]. In addition, IgG4 itself
seems to be unable to activate the classic complement
pathway. Another characteristic feature of IgG4 antibodies
is the possible occurrence of Fab arm exchange of these
antibodies [38]. This is due to weak bonds between the
heavy chain of the IgG4 antibodies thus allowing the Fab
arm exchange and formation asymmetric bispecific anti-
bodies. This further hampers antigen cross-linking and
immune complex formation of IgG4 antibodies. Nonethe-
less, there is evidence of importance and pathogenicity of
IgG4 antibodies in human diseases. Certain autoantibody
immune mediated diseases such as membranous GN and
thrombotic thrombocytopenic purpura seem to be medi-
ated by antibodies of the IgG4 type [39,40].
Interestingly, low C3 and C4 complement levels can
be observed in one third of IgG4-RD patients with renal
involvement indicating immune complex formation [15].
In type 1 AIP, tissue deposition of C3c, IgG4 and IgG
can be observed at the basement membrane of pan-
creatic and bile ducts and of acini [41]. C3 and IgG
deposition can also be observed at the tubular basement
membrane in IgG4- related tubulointerstitial nephritis
(TIN) [15]. Thus, immune complex mediated tissue
damage may occur at least in some organ manifestations
of IgG4-RD.
Recent insights into the pathophysiology of IgG4-RD
suggest that one of the major drivers of the disease ap-
pear to be plasmablasts. Oligoclonal expanded plasma-
blasts with extensive somatic hypermutation were found
to be increased in IgG4-RD patients with active disease.
Of interest, depletion of B cells with rituximab leads to a
reduction of these plasmablasts and correlates with dis-
ease remission [42]. Compared to other inflammatory
diseases before treatment and healthy controls, circulat-
ing plasmablasts are elevated in patients with active
IgG4-RD, even in those patients with normal serum
IgG4 concentrations. This observation poses plasma-
blasts as potential biomarkers for diagnosis and assess-
ment of treatment response [43].
Clinical manifestations
Pancreas
Type 1 AIP is the classical presentation of IgG4-RD,
while type 2 AIP is not part of the IgG4 spectrum, has
distinct histopathological features such as ductal neutro-
philic abscesses and ductal injury and is not reviewed
here in detail [44]. Type 1 AIP is rare, being the cause of
chronic pancreatitis in less than 5% of cases. It typically
occurs in middle-aged males [45]. IgG4 serum levels are
usually elevated, but are normal in up to 20% of patients.In contrast, elevated levels of IgG4 are uncommon in
type 2 AIP [46]. Obstructive jaundice is a common symp-
tom at presentation, while pain may be absent [44,45]. In
addition, extra-pancreatic organ involvement is frequent
in type 1 AIP, thereby representing the systemic nature of
IgG4-RD.
Imaging techniques can provide clues to the diagnosis
of AIP. Magnetic resonance cholangiopancreatography
(MRCP) and endoscopic retrograde cholangiopancreato-
graphy (ERCP) may demonstrate pancreatic duct stric-
tures and/or stricture of the common bile duct as well as
irregular narrowing of intrahepatic ducts. Complete oblit-
eration of the bile duct is unusual. Computed tomography
(CT) and magnetic resonance (MR) imaging show focal or
diffuse pancreatic enlargement, a peripancreatic capsule-
like rim, and late phase contrast-enhancement, which is
believed to correspond to peripheral inflammation and
fibrosis [38,47].
While radiological and serological studies as well as
clinical symptoms may help to establish the diagnosis, in
less characteristic cases the final diagnosis needs to be
based on histological tissue examination. In type 1 AIP a
typical diffuse lymphoplasmacytic infiltrate and a stori-
form fibrosis are evident. IgG4-positive plasma cells are
usually found >50 per high-power field (HPF). Oblite-
rative phlebitis is common, but may be masked by the
inflammatory infiltrate. In such cases, an elastic stain
can be helpful. Tissue eosinophils are also frequently
found. Of note, while there may be a periductal infiltrate,
the ductal epithelium – in contrast to type 2 AIP - is pre-
served [48]. Diagnostic criteria for the diagnosis of AIP
have been published [24].
Unfortunately, AIP shares many similarities with pan-
creatic cancer, such as age, male predominance, painless
jaundice or swelling of the pancreas [49]. This may be of
special relevance in the case of “localized” AIP, which
can lead to a tumorous appearance of the pancreatic
head. In one large series 2.2% of patients undergoing
pancreaticoduodenectomy were diagnosed retrospectively
with AIP (“lymphoplasmacytic sclerosing pancreatitis”).
Of these cases the preoperative diagnoses were pancreatic
cancer in 53%, periampullary neoplasm in 38%, and chol-
angiocarcinoma in 9% [50]. Thus, a thorough work up is
essential before either surgery or steroid treatment is
planned. Of note, solely relying on elevated IgG4 levels
may be misleading, as these may also be increased in pan-
creatic cancer. The notion that pancreatic cancer can
develop in patients with definitive AIP further complicates
the management of these patients [51].
Bile ducts, gallbladder and liver
The most characteristic clinical sign of IgG4- related
cholangitis at presentation is obstructive jaundice. IgG4-
related cholangitis typically affects large bile ducts, while
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the bile ducts, the gallbladder seems to be involved in
a substantial proportion of cases [54]. The intrapan-
creatic bile duct as well as more proximal parts of
the ducts are typically affected. A localized diffuse
thickening of the bile duct is characteristic, but mul-
tiple strictures may occur. Increased IgG4 levels are
found in approximately 80% of the patients. Strikingly,
92% of patients in both mentioned series had concomitant
type 1 AIP.
Histological features of IgG4-related cholangitis are
similar to those found in other organs affected by IgG4-
RD. Liver biopsies may be inconclusive for a final diagno-
sis of IgG4-related cholangitis. However, a high number of
patients with AIP demonstrate pathological features on
liver biopsies. The picture does not appear to be uniform
in all patients and is composed of portal inflammation
(with or without interface hepatitis), large bile-duct
obstructive features, portal sclerosis, lobular hepatitis, and
canalicular cholestasis. Multiple features can coexist in
single patients [55]. Whether there exists a true “IgG4-re-
lated autoimmune hepatitis” or not is a matter of discus-
sion, but a minority of patients with autoimmune hepatitis
may in fact have an IgG4-RD [56].
If patients are diagnosed with type 1 AIP and have in
addition characteristic manifestations on imaging in
combination with elevated IgG4 levels, then a diagnosis
of IgG4 related cholangitis is usually straightforward.
However, in the absence of AIP a histological tissue
examination will be required in most patients. Different
strategies for tissue sampling are possible. Ampullary
biopsies are rather easy to obtain. Sensitivity for IgG4
positive cells is 50%, but samples from this site are lack-
ing information on storiform fibrosis. Bile duct biopsies,
which are more challenging to perform, have the same
sensitivity for IgG4 positive cells but can demonstrate
the full spectrum of pathological features of IgG4-RD.
Liver biopsies are invasive and have a sensitivity of only
20% for IgG4 positive cells. However, liver biopsy may
be especially helpful in the consideration of differential
diagnoses [53].
Neoplastic disease is a main differential diagnosis of
IgG4-RD in bile ducts, gallbladder, and liver. Cholangio-
cellular carcinoma has to be excluded and the differenti-
ation of carcinomas to IgG4-RD can provide difficulties
[57]. IgG4 levels can be misleading, as patients with
cholangiocarcinoma – as well as with other forms of
cancer and a broad range of other diseases – can have
moderately elevated IgG4 levels [57]. Further potential
mimics of IgG4-related sclerosing cholangitis include
follicular cholangitis, primary sclerosing cholangitis and
sclerosing cholangitis with granulocytic epithelial lesion
(the latter probably being the bile duct counterpart of
type 2 AIP) [58-60].Thyroid gland
Since 2010, Riedel’s thyroiditis is considered part of the
IgG4-RD spectrum [61]. In contrast to most manifes-
tations of IgG4-RD, Riedel’s thyroiditis has a female pre-
ponderance. Riedel’s thyroiditis may affect a lobe or the
total thyroid gland. A specific finding is the extension of
the fibrotic mass into adjacent tissues. This process can
lead to invasion of the parathyroid glands (thereby caus-
ing hypoparathyroidism), skeletal muscles, nerves, blood
vessels, as well as the trachea [62]. Clinical symptoms
include pain, local swelling, dysphagia, hoarseness, or
symptoms due to tracheal narrowing [63,64]. A definitive
diagnosis requires histopathologic examination. Indeed,
most patients undergo surgery because of suspected ma-
lignancy, as fine needle aspiration is frequently inconclu-
sive. At surgery a clear differentiation between anatomic
structures is often difficult due to the invasive nature of
the fibrotic mass. Therefore, a complete thyroidectomy is
seldom performed. Recently, the fibrosing variant of
Hashimoto’s thyreoiditis, which remains localized to the
thyroid gland, emerged as being also a part of the
IgG4-RD spectrum [65].
Salivary and lacrimal glands
Salivary and lacrimal glands are frequently affected in
IgG4-RD. Chief complaints include a persistent asymmet-
ric or symmetrical swelling of the involved glands and
impaired secretion. Pain is uncommon [66]. IgG4-related
sialadenitis and dacryoadenitis seem to affect both sexes
equally. Age at onset shows a wide range with a mean of
approximately 60 years [67,68]. Chronic sclerosing sialade-
nitis can present with mass lesions ranging up to 5 cm.
Microscopic examination shows some distortion but over-
all preservation of the lobular architecture and a dense
lymphoplasmacytic infiltrate with numerous hyperplastic
lymphoid follicles. The classical features of IgG4-RD are
usually found. A similar picture is found in IgG4-related
dacryoadenitis [69,70].
One of the major mimics of Mikulicz disease is SS
[71]. In fact, formerly Mikulicz syndrome and SS were
considered closely related [72]. From a clinical perspec-
tive, SS usually never affects the submandibular glands
isolated. In contrast to IgG4-RD, SS patients frequently
have anti-SS-A and/or anti-SS-B autoantibodies but do
not generally exhibit elevated serum IgG4 levels [66]. It
is very likely that a substantial proportion of patients
with “ANA negative SS” will in fact have IgG4-RD.
Histopathological differences are helpful to distinguish
both diseases. IgG4+ plasma cell infiltration in tissue is
frequent in patients with IgG4-RD, but not in SS. Expan-
sion of IgG4+ plasma cells with fibrosis or sclerosis is an
important histopathological finding in IgG4-RD, but
unusual for SS. Lymphocytic follicle formation is com-
monly observed in IgG4-RD, but lymphocytic infiltration
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rare [73].
Other diseases that need to be distinguished from
IgG4-related sialadenitis and dacryoadenitis are lymph-
omas, sialolithiasis and carcinomas. The latter may be
surrounded by an inflammatory infiltrate containing
IgG4 positive plasma cells complicating the exact diag-
nosis [69].
Orbits
Orbital tumors of the ocular adnexa consist of a hetero-
geneous group. A large proportion of these tumors are
lymphoproliferative disorders (LPDs). These LPDs repre-
sent malignant lymphomas and a diverse group of orbital
inflammations, such as reactive lymphoid hyperplasia or
infiltration [74]. Several structures within the orbital cavity
and adjacent structures such as extraocular muscles,
nerves (including the supra- and inraorbital as well as
optic nerve), periorbital membrane and lacrimal sac can
be affected. Chronic lid swelling and proptosis are com-
mon clinical signs. Pain is unusual. If extraocular muscles
are involved eye motility can be restricted. Visual distur-
bances can occur if the optic nerve is involved [75].
Lesions may appear as a tumefactive mass [76,77]. The
fibroinflammatory tissue can extend into the pterygo-
palatine fossa and cavernous sinus. Bone destruction is an
unusual sign, but has been reported [78,79].
Pathohistologically, characteristic signs of IgG4-RD
can be found, but obliterative phlebitis seems to be rare
[75]. Rather, fibrosis is a prominent feature, which may
relate also to duration of disease. However, the storiform
pattern seems to be less common than in other organs
affected by IgG4-RD [69].
Retroperitoneal fibrosis and large vessel involvement
Retroperitoneal fibrosis (RPF) is a rare disease character-
ized by the occurrence of fibrosis in the retroperitoneum.
RPF usually affects adult middle-aged males and is
strongly associated with smoking [80]. Clinical manifesta-
tions can vary considerably. In some patients findings may
be incidental, other patients present with back pain. In
some cases manifestations of IgG4-RD in other organs
leads to work up, thereby elucidating retroperitoneal
fibrosis and/or aortitis. Hydronephrosis due to ureteral
entrapment is a common complication [81]. Periaortitis is
asymptomatic in most patients. In rare cases a rupture
after aneurysmal transformation can occur [82].
On CT imaging circumferential arterial wall thicken-
ing, which is caused by sclerosing inflammation in the
adventitia, is characteristic. Plaque-like lesions can also
be seen. Of note, perivascular lesions are usually promin-
ent. Affected vessels demonstrate homogeneous enhance-
ment at the late phase of contrast–enhanced CT. Some
cases show dilated lumen of the affected vessels. Arteriespenetrating the fibroinflammatory process surrounding
the aorta are usually patent [81]. Histopathology can show
typical features of IgG4-RD, but in long-standing disease,
fibrosis rather than inflammation may be the dominant
finding.
RPF is closely linked to inflammatory aortic aneurysm
and thoracic aortitis and is therefore now being summa-
rized as chronic periaortitis [83]. RPF itself seems to be
a heterogeneous group of diseases. Some patients show
signs of IgG4-RD but many patients have isolated RPF
[84]. Inflammatory abdominal aortic aneurysms may also
be part of the IgG4-RD spectrum [85]. IgG4-RD mainly
affects the aorta but also frequently involves its main
branches. In one study 9% of noninfectious aortitis cases
of the thoracic aorta were caused by IgG4-RD [86]. Of
interest, while both the thoracic aorta and the infrarenal
aorta are predominant sites of involvement the supra-
renal abdominal aorta seems to be spared [81]. Besides
the aorta and its main branches, also peripheral arteries
are sites of involvement of IgG4-RD [87]. IgG4-related
aortitis mainly involves the adventitia. However, the
media can also be affected and the lamellar elastic fibers
can be disrupted. The latter seems to be associated with
aneurysmal transformation [12,81].
Intrapulmonary, mediastinal and pleural involvement
IgG4-RD can affect the airways, pleura and mediasti-
num. Patients may present with cough, dyspnea, chest
pain or frequently remain asymptomatic [88,89]. Intra-
pulmonary manifestations include nodules and mass
lesions (“inflammatory pseudotumors”) but may also
present as interstitial lung disease. In the visceral and
parietal pleura, IgG4-RD can cause nodular lesions [90].
In the same patients, bronchial inflammation, edema,
and stenosis may occur [91]. In addition, mediastinal
fibrosis is another clinical syndrome proposed to lie within
the spectrum of IgG4-RD.
Imaging studies reflect the diverse nature of morpho-
logical manifestation of IgG4-related lung disease. A re-
cent study categorized lung findings on imaging into four
major subtypes: solid nodular type (nodule or mass); (mul-
tiple) round-shaped ground-glass opacity type; alveolar
interstitial type (bronchiectasis, honeycombing and diffuse
ground-glass opacities); and bronchovascular type (with
thickening of bronchovascular bundles and interlobular
septa) [89].
Diagnosis of IgG4-RD in the lungs can be challenging.
The lung tends to show a stereotypic morphologic
response to a variety of different injuries. Thus, diffe-
rential diagnostic considerations can be difficult. While
fibrosis and obliterative vascular changes are common in
solid areas, a characteristic storiform pattern may be lack-
ing on tissue samples. While eosinophils are common
as it is the case in other sites of IgG4-RD manifestations,
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ture of IgG4-related lung disease is that pulmonary veins
as well as arteries can be affected [90]. A number of dis-
eases can mimic IgG4-related lung disease, including lung
cancer, idiopathic interstitial pneumonia, LPD, and sar-
coidosis [89]. Thus, the field of differential diagnoses is
broad.
Lymph nodes
Localized or systemic involvement of lymph nodes is
common in IgG4-RD [93]. Differential diagnosis is broad
including lymphomas, metastatic disease, Castleman’s
disease and other immune mediated or hematological
diseases. Fever, weight loss and night sweats, however,
are uncommon in IgG4-RD [94]. Interestingly, histo-
pathology of lymph nodes in IgG4-RD differs from the
usual findings. Storiform fibrosis and obliterative phle-
bitis are usually absent in affected lymph nodes [11].
Findings include the following: multicentric Castleman’s
disease-like, reactive follicular hyperplasia-like, interfolli-
cular expansion and immunoblastosis; progressively
transformed germinal center type; and inflammatory
pseudotumor-like IgG4-related lymphadenopathy [94].
It is important to recognize that the histopathology of
lymph nodes in suspected IgG4-RD is usually not
straightforward when used as a sole criterion for diag-
nosis. Thus, it may be difficult to clearly distinguish IgG4-
related lymphadenopathy from other disease. However, it
may be important to take lymph node biopsies to exclude
e.g. malignancy.
Kidney
The main manifestations of IgG4-RD in the kidney is
tubulointerstitial nephritis and membranous GN [95,96].
The disease can clinically present as acute or chronic
renal failure, renal mass lesions, or both. Contrast-
enhanced CT scans of patients with IgG4-related tubu-
lointerstitial nephritis shows mostly bilateral and multiple
renal parenchymal lesions, predominantly involving the
renal cortex. These lesions may appear as small periph-
eral cortical nodules, well defined or ill-defined round
lesions, wedge-shaped lesions or diffuse patchy. In some
cases a mass effect can be present. Extraparenchymal
involvement can be found in the form of a diffuse rim of
soft tissue surrounding the kidney, irregular nodules in
the renal sinuses or diffuse wall thickening of the renal
pelvis [97].
Histopathology shows typical fibrosis and a lymphoplas-
macytic infiltrate with a high number of IgG4 positive
cells. IgG and/or C3 granular deposits on the tubular
basement membrane are present in a significant number
of patients. In addition, a variety of glomerular lesions,
mainly different forms of glomerulonephritis, may be add-
itionally present in such patients. All this has raised thesuspicion that immune complexes are involved in the
pathogenesis of IgG4-related tubulointerstitial nephritis
[15]. Of interest, in some cases tubules are destroyed [98].
This seems to be somewhat in contrast to other mani-
festations of IgG4-RD, where the epithelium is usually
preserved (e.g., salivary glands, bile ducts and pancreas).
In some patients, a secondary form of membranous GN
develops lacking classical IgG4-RD histopathological fea-
tures such as storiform fibrosis or obliterative phlebitis. Of
interest, a substantial proportion of patients with idio-
pathic membranous nephropathy have autoantibodies of
the IgG4 class that bind to the M-type phospholipase A2
receptor. In contrast, patients with IgG4RD do not show
such antibodies, regardless of the presence or absence of
membranous nephropathy [13,99].
Miscellaneous
Several structures of the nervous system were found to
be involved in IgG4-RD. Peripheral nerves have been re-
ported to be affected by IgG4-RD. Common sites of
manifestations are the orbital and spinal nerves with
predominant infiltration of the epineurium (“perineural
disease”). Of interest, neurologic symptoms are seldom
which seems to be related to the fact that nerve fascicles
are usually intact and not damaged [100]. In the pituary
gland, IgG4-RD disease can cause hypophysitis [101,102].
IgG4-related inflammatory pseudotumors may arise dir-
ectly within the central nervous system [103]. Roughly
one third of cases with hypertrophic pachymeningitis
appear to be due to IgG4-RD [104].
Idiopathic cervical fibrosis, a rare sclerosing disease of
the neck, seems to be part of the IgG4-RD spectrum
[105]. A unusual form of mastitis, sclerosing mastitis,
which can present as painless masses in the breasts, has
also been reported to be a manifestation of IgG4-RD
[106]. In men, IgG4-RD can be the cause of prostatitis,
orchitis as well as paratesticular pseudotumors [107-109].
In some cases IgG4-RD can involve the skin, presenting as
erythematous and itchy plaques or subcutaneous nodules
[110]. The pericardium has been reported to be a site of
manifestation of IgG4-RD, resulting in constrictive peri-
carditis [111,112]. Eosinophilic angiocentric fibrosis, a rare
tumefactive lesion of the orbit and upper respiratory
tract, has also been supposed to be a manifestation of
IgG4-RD [113].
Treatment
Overall, there is no evidence for treatment options from
randomized controlled trials. Clinical experience is that
most IgG4-RD patients respond favorably to glucocortic-
oid (GC) treatment. The effect of GCs has been reported
for several sites of IgG4-RD manifestations in different
cohort studies. While it appears that spontaneous remis-
sions do occur [114], the use of GCs induces remission
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However, relapse is frequently seen after GCs are tapered
or stopped [52]. Relapses may be confined to the ori-
ginally affected organs but also occur in other organs.
They may be preceded or accompanied by an increase
in IgG4 levels [115,116].
Whether treatment in patients with IgG4-RD needs to
be established depends on the localization and extent of
disease manifestation. In some patients with minor
involvement (e.g. asymptomatic and incidentally found
IgG4-related lymphadenopathy or small, indolent nodu-
lar lesions in IgG4-related lung disease), immediate
treatment may not be indicated and follow-up may be
more appropriate. In other cases with organ dysfunction
or pseudotumors (e.g., renal involvement, AIP with bile
duct obstruction and jaundice, lacrimal gland swelling,
pachymenigitis, etc.) rapid introduction of therapy is ne-
cessary to avoid loss of organ function. Thus, treatment
decision has to be individualized [117]. Most cohort
studies report on IgG4-RD patients with a particular
organ involvement, which may not translate to other
organ manifestations. Moreover, a substantial propor-
tion of publications are from Asian IgG4-RD patients,
questioning whether these data also apply to non-
Asian patients.
In general, most experts would start with a dosage of
40 mg prednisolone or 0.6 mg/kg of body weight per
day and taper the dose over several months, starting
with a first dose reduction after 2–4 weeks [117-119].
Treatment response is usually seen within two to four
weeks. Major drawbacks of GCs are side effects as well
as the need for maintenance therapy. Thus, a number
of drugs such as azathioprine, mycophenolate mofetil
or methotrexate have been used as GC sparing agent
[119-123]. In addition, more intensive therapies such
as cyclophosphamide, fludarabine and bortezomib
have been reported to be of benefit in IgG4-RD pa-
tients [123-125].
A promising treatment strategy in GC- dependent or
refractory patients is rituximab (RTX) [84,120,126]. RTX
has been used in a case series of 10 refractory IgG4-RD
patients. The duration of treatment effect is not
established. Not surprisingly, relapse of IgG4-RD after
rituximab treatment has been reported [127]. One
major interesting finding was that RTX specifically re-
duced IgG4 levels, while the other IgG subclasses
remained stable. This has led to the hypothesis that
short lived plasma cells producing IgG4 are involved in
the disease [84,120].
Conclusions and future perspectives
Over the last decade a number of previously thought
unrelated diseases have been recognized as a spectrum
of a single disease. Terminology and diagnostic criteriahave since been worked out [10,22]. However, as with
every “new” disease a lot of enthusiasm might arise. This
can lead to the situation that uncommon conditions are
not only underdiagnosed, but eventually also overdiag-
nosed. While it is straightforward for most IgG4-RD
manifestations to be accepted as part of the IgG4-RD
spectrum, for other manifestations no final conclusions
can be drawn to date, as only few cases have been re-
ported, so far. Within the future it has to be clarified
whether all of the nowadays suspected diseases truly
belong to IgG4-RD spectrum.
Currently, GCs are considered the first line therapy,
but randomized trials to determine optimal dose and
duration are warranted. In addition, data on the effect of
other immunosuppressants are very limited. Further
points that need to be addressed in the future are whether
all organ manifestations respond similar to treatment and,
finally, it needs to be investigated whether non-Asian pop-
ulations do behave similar to Asian patients, for whom
most data are published to date.
Further, it remains unclear, how IgG4-RD patients should
be followed. IgG4 seems to have some characteristics of a
biomarker in patients with elevated IgG4 levels, but it is
unclear whether IgG4 levels can be used to guide therapy
for instance [128]. Future research will include the search
for further biomarkers for diagnosis and/or follow up of
IgG4-RD patients. One possible useful biomarker seem to
be circulating plasmablasts [42,43]. Whether expensive
imaging modalities such as PET-CT, will become part of
routine care of IgG4-RD patients or not, needs to be
further investigated [129]. Finally, we do not understand
the pathophysiology of the disease, which could lead to the
invention of specific therapies for this rare disease.
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